OncoMatch/Clinical Trials/NCT05595603
Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage
Is NCT05595603 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for giant cell tumor of bone.
The purpose of this study is to investigate whether zoledronic acid-loaded bone cement (4mg ZOL+ gentamicin PMMA ) as adjuvant method can decrease local recurrence in patients with giant cell bone tumor following intralesional curettage surgery. The hypothesis is that patients with local administration of zoledronic acid to the bone cement has lower relapse rate compared those with traditional bone cement(gentamicin PMMA ).
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: bisphosphonate (zoledronic acid)
no previous systemic bisphosphonate or denosumab therapy; previous use of bisphosphonate/ZOL or denosumab drug
Cannot have received: RANKL inhibitor (denosumab)
no previous systemic bisphosphonate or denosumab therapy; previous use of bisphosphonate/ZOL or denosumab drug
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify